VERAXA Biotech (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany

Questions around this news

What is regulatory Scientific Advice?
Scientific Advice is a process in which a drug developer seeks feedback from a medicines regulator on aspects of a planned development program. It can help clarify how the regulator views topics such as scientific rationale, safety testing and non-clinical studies. It is guidance for development planning, not the same as authorization to begin a clinical trial or market a medicine.
Does Scientific Advice mean the candidate is approved for clinical trials?
No. Scientific Advice is regulatory feedback intended to inform a developer’s plans; it is not itself approval to conduct a clinical trial. The release describes the advice as early guidance and says the company is preparing its candidate for future clinical development. It does not report that a clinical trial has been authorized or begun.
What other types of cancer therapies are in VERAXA’s pipeline?
The release says the company is building an oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates and other engineered antibody formats. It does not provide further details about those programs in the supplied text. The regulatory feedback described in the announcement concerns the lead BiTAC-TCE program.

The company has received Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”) supporting the proposed development strategy for its lead BiTAC(R)-TCE program.
The regulatory feedback provides early guidance on the company’s biological rationale, safety assessments, and non-clinical development plan, for its novel therapeutic platform.
VERAXA believes the advice helps reduce development uncertainty by providing greater clarity before advancing toward clinical studies.
The company’s lead BiTAC(R)-TCE candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting.
VERAXA continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (“ADCs”) and other engineered antibody formats.
The latest regulatory milestone follows continued progress in manufacturing and development as the company advances next-generation antibody therapeutics for cancer.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has taken another step in the development of its proprietary BiTAC(R)-TCE platform after receiving Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”), providing regulatory feedback on the biological rationale and proposed non-clinical development strategy for its lead therapeutic program. The announcement, released on July 20, signals progress as the biotechnology company prepares its most advanced BiTAC(R)-TCE candidate for future clinical development (https://ibn.fm/zBiDU).

Scientific Advice procedures allow drug developers to consult with regulatory experts before clinical trials begin, helping companies align their development strategies with regulatory expectations regarding safety, tolerability and…

At a glance

Company: VERAXA Biotech
Ticker: NASDAQ: VRXA
Announcement: Regulatory
Location: Germany

Products and programs

BiTAC-TCE
Bispecific T-cell engagers
Antibody-drug conjugates (ADCs)
Other engineered antibody formats

SEC filings

Earlier from VERAXA Biotech

Back to News Center

VERAXA Biotech (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany

Questions around this news

What is regulatory Scientific Advice?

Does Scientific Advice mean the candidate is approved for clinical trials?

What other types of cancer therapies are in VERAXA’s pipeline?

At a glance

Products and programs

SEC filings

Earlier from VERAXA Biotech